Clinical Trial Update: A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tucatinib in combination with trastuzumab and capecitabine in patients with previously treated locally advanced unresectable or metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Trastuzumab (trastuzumab)
• Tucatinib (tucatinib)

Snippet

Sponsor: Pfizer | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-08-09